UNSPSC 51285004: Ceftolozane/Tazobactam

Ceftolozane/tazobactam is a combination antibiotic medication used for the treatment of complicated urinary tract infections and complicated intra-abdominal infections in adults. Ceftolozane is a cephalosporin antibiotic, developed for the treatment of infections with gram-negative bacteria that are resistant to conventional antibiotics. It was studied for urinary tract infections, intra-abdominal infections and ventilator-associated bacterial pneumonia.

UNSPSC 51285004 Ceftolozane/Tazobactam is a Commodity code for a specific antibiotic pharmaceutical product, but the recent state and local opportunities block shows minimal direct solicitation activity tied to this code. The block contains one pharmaceutical procurement (Seminole County's Naloxone and Safe Drug Deactivation Systems, an IFB issued June 30, 2026, with a response date of July 26, 2023—a date inconsistency suggesting data quality issues), one multi-source generic pharmaceutical cooperative vehicle (MMCAP's generic pharmaceuticals and OTC contract, RFP due March 26, 2026), and one complex EMS supply contract from Tucson Fire Department (RFP 260217, due June 24, 2026, covering BLS/ALS pharmaceuticals and vending systems). The remaining opportunities are vendor networking events, trade shows, grant application windows, and departmental forums rather than active procurements. The code shows no standout repeat buyers pursuing ceftolozane/tazobactam specifically.

State and local pharmaceutical procurement under this code typically flows through three channels: direct hospital and health system purchasing (not visible in this block), cooperative purchasing vehicles like MMCAP that aggregate demand across multiple jurisdictions and states, and emergency medical services supply contracts bundled with broader clinical supply packages. Geographic activity is sparse in the recent records, with mentions of Minnesota (MMCAP), Florida (Seminole County, Tucson), and Arizona (Tucson). The code itself lacks sufficient current solicitation momentum to support a pursue decision; activity appears episodic and merged into broader pharmaceutical, OTC, or emergency supply bundles rather than as discrete opportunities for ceftolozane/tazobactam alone. Firms should monitor MMCAP and regional health system RFPs for indirect access to this drug class through multi-source generic pharmaceutical awards.